iBio (IBIO) Change in Receivables (2011 - 2025)

iBio (IBIO) posted quarterly Change in Receivables of $65000.0 for Q3 2025, up 194.2% quarter-over-quarter from -$69000.0 in Q2 2023.

iBio (IBIO) Change in Receivables (2011 - 2025) Analysis & Trends

iBio (IBIO) has reported Change in Receivables for 13 consecutive years, with $65000.0 the latest figure, recorded in Q3 2025.

In Q3 2025, Change in Receivables changed N/A year-over-year to $65000.0; the TTM figure through Mar 2026 stood at $65000.0 (up 194.2% YoY), while the FY2023 annual figure was -$1.0 million, down 212.87% from the prior year.
Change in Receivables grew to $65000.0 in Q3 2025 per IBIO's latest filing, from -$69000.0 in the prior quarter.
Across five years, Change in Receivables topped out at $893000.0 in Q1 2022 and bottomed at -$900000.0 in Q1 2023.
Historically, Change in Receivables has averaged $24818.2 across 4 years, with a median of $54000.0 in 2022.
Annual changes were most pronounced in 2022 — Change in Receivables soared 329.33% — and 2023, when it tumbled 1625.0%.
iBio's Change in Receivables stood at -$96000.0 in 2021, then grew by 11.46% to -$85000.0 in 2022, then gained by 18.82% to -$69000.0 in 2023, then surged by 194.2% to $65000.0 in 2025.
Business Quant data shows IBIO's Change in Receivables at $65000.0 in Q3 2025, -$69000.0 in Q2 2023, and -$900000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	140.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	838.50 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-53.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	117.58 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	31.60 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	94.29 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	37.16 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	iBio	172.22 Mn	172.22 Mn	-	-

Download Data